Synthaverse S.A. Cash Flow Conversion Efficiency
Synthaverse S.A. cash flow conversion efficiency. Based on the latest financial reports, Synthaverse S.A. (SVE) has a cash flow conversion efficiency ratio of 0.072x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł8.68 Million ≈ $2.39 Million USD) by net assets (zł120.93 Million ≈ $33.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Synthaverse S.A. (2010–2024)
Cash flow conversion efficiency of Synthaverse S.A. from 2010 to 2024. This chart illustrates how Synthaverse S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Synthaverse S.A. share price for real-time trading data and today's change.
Synthaverse S.A. Cash Flow Conversion Ratio Explained
Synthaverse S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Synthaverse S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synthaverse S.A. ranked by their cash flow conversion efficiency. Also see SVE company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Supremex Inc.
TO:SXP
|
0.039x |
|
Xin Chio Global Co Ltd
TWO:3171
|
0.084x |
|
Broad Capital Acquisition Corp
NASDAQ:BRAC
|
0.008x |
|
Saehwa IMC Co Ltd
KO:145210
|
0.026x |
|
ADOLFO DOMINGUEZ
MC:ADZ
|
0.253x |
|
An Gia Real Estate Investment and Development Corp
VN:AGG
|
-0.015x |
|
Reitmans (Canada) Limited
V:RET-A
|
0.214x |
|
Hil Industries Bhd
KLSE:8443
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Synthaverse S.A. (2010–2024)
The table below shows the annual cash flow conversion efficiency of Synthaverse S.A. from 2010 to 2024. Review SVE cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł121.47 Million ≈ $33.43 Million |
zł13.73 Million ≈ $3.78 Million |
0.113x | +338.13% |
| 2023-12-31 | zł112.64 Million ≈ $31.00 Million |
zł-5.34 Million ≈ $-1.47 Million |
-0.047x | -269.91% |
| 2022-12-31 | zł105.56 Million ≈ $29.05 Million |
zł2.95 Million ≈ $811.33K |
0.028x | +163.46% |
| 2021-12-31 | zł74.55 Million ≈ $20.52 Million |
zł-3.28 Million ≈ $-902.98K |
-0.044x | -578.66% |
| 2020-12-31 | zł37.31 Million ≈ $10.27 Million |
zł343.00K ≈ $94.40K |
0.009x | -96.30% |
| 2019-12-31 | zł32.87 Million ≈ $9.05 Million |
zł8.16 Million ≈ $2.25 Million |
0.248x | +1317.34% |
| 2018-12-31 | zł30.40 Million ≈ $8.37 Million |
zł-620.00K ≈ $-170.63K |
-0.020x | -127.07% |
| 2017-12-31 | zł57.81 Million ≈ $15.91 Million |
zł4.36 Million ≈ $1.20 Million |
0.075x | -99.46% |
| 2016-12-31 | zł1.13 Million ≈ $310.17K |
zł15.77 Million ≈ $4.34 Million |
13.993x | +9585.14% |
| 2015-12-31 | zł20.00 Million ≈ $5.51 Million |
zł-2.95 Million ≈ $-812.18K |
-0.148x | -566.59% |
| 2014-12-31 | zł57.25 Million ≈ $15.76 Million |
zł-1.27 Million ≈ $-348.68K |
-0.022x | +81.02% |
| 2013-12-31 | zł58.49 Million ≈ $16.10 Million |
zł-6.82 Million ≈ $-1.88 Million |
-0.117x | +37.91% |
| 2012-12-31 | zł44.75 Million ≈ $12.32 Million |
zł-8.40 Million ≈ $-2.31 Million |
-0.188x | +42.69% |
| 2011-12-31 | zł50.06 Million ≈ $13.78 Million |
zł-16.41 Million ≈ $-4.51 Million |
-0.328x | -268.73% |
| 2010-12-31 | zł14.06 Million ≈ $3.87 Million |
zł-1.25 Million ≈ $-343.86K |
-0.089x | -- |
About Synthaverse S.A.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more